PRX-07034

Chemical compound
  • none
Legal statusLegal status
  • In general: uncontrolled
Identifiers
  • N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
CAS Number
  • 903580-16-5
PubChem CID
  • 11532574
ChemSpider
  • 9707357
UNII
  • YJ5TMF911R
Chemical and physical dataFormulaC21H29Cl2N3O4SMolar mass490.44 g·mol−13D model (JSmol)
  • Interactive image
  • COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
InChI
  • InChI=1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3
  • Key:BSLXKMCHXRCBIH-UHFFFAOYSA-N
  (verify)

PRX-07034 is a selective 5-HT6 receptor antagonist.[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.[1][2][3][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][7]

References

  1. ^ Fone KC (November 2008). "An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function". Neuropharmacology. 55 (6): 1015–22. doi:10.1016/j.neuropharm.2008.06.061. PMID 18655798. S2CID 35522597.
  2. ^ Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity". Drugs. 67 (1): 27–55. doi:10.2165/00003495-200767010-00004. PMID 17209663. S2CID 46972692. Archived from the original on 2013-01-05. Retrieved 2010-03-09.
  3. ^ "PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials".
  4. ^ "Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009".
  5. ^ "Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction".

External links

  • Preclinical Data on Predix Pharmaceuticals' 5-HT6 Antagonist for Obesity and Cognitive...
  • Epix’s Experimental Drug PRX-07034 Shows Potential Benefit on Cognition, Obesity
  • v
  • t
  • e
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonistsGLP-1, GIP, and / or
glucagon agonistsDACRAs5-HT2C
receptor agonistsAbsorption inhibitorsUncouplersOthers
  • v
  • t
  • e
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Dopaminergics
  • Melatonergics
  • Monoamine reuptake inhibitors and releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins